The Medicines and Healthcare products Regulatory Agency (MHRA) recently issued a caution relating to a drug that treats adult patients with active rheumatoid arthritis or active psoriatic arthritis.<\/p>\n
Global pharmaceutical company\u00a0Sanofi informed the medical agency of the error on the Braille on the packaging of some batches of the Arava 10mg film-coated tablets. The affected batches were distributed in May 2016, August 2016,\u00a0 September 2016 and October 2016 with batch numbers 5JK2A, 5JK3A, 5JK6G and 6EV2A accordingly.
\n<\/p>\n
On the affected batches, the strength of the product is incorrect: reading ’20mg’ instead of ’10mg’ in Braille. The printed text on all packaging is correct. Of course, this should only affect the visually impaired relying on Braille for the strength of the tablets. There is a danger, and affected packs shouldn’t be distributed or dispensed to patients who rely solely or heavily on Braille to determine the strength of the tablets.<\/p>\n
There is an alternative batch available for patients who rely solely on Braille; batch number 6GL5E. Distributors of Arava are encouraged to contact Sanofi Customer Services on 0800 854 430<\/strong> if their wholesaler doesn’t have this batch in stock. It’s important that distributors have this alternative batch as there’ll be patients who rely on Braille exclusively.<\/p>\n The drug alert has recently been issued by the medical agency to all healthcare professionals. NHS regional teams who are in receipt of the letter should forward the alert to relevant clinics, dispensing GPs and community pharmacists.<\/p>\n The drug alert has been classified as a class 4 caution. A class 4 advises caution in use, indicating that the product doesn’t pose a threat to patient safety. As a general rule, medical alerts are graded according to the seriousness of the threat to the public’s health. They’re graded from class 1 to class 4.<\/p>\n Drug recalls are based on a tiered structure:<\/p>\nClasses of drug recalls\/medical alerts<\/h3>\n